tetano
Editor, Senior Moderator
Clin Infect Dis
. 2025 Mar 8:ciaf101.
doi: 10.1093/cid/ciaf101. Online ahead of print. Evaluation of influenza antiviral prophylaxis for long-term care residents: a systematic review and meta-analysis
Ryan Hanula[SUP] 1 2 [/SUP], Jessica Glugosh[SUP] 3 [/SUP], Elise Van Leer[SUP] 4 [/SUP], Émilie Bortolussi-Courval[SUP] 1 2 [/SUP], Connor Prosty[SUP] 5 [/SUP]
Affiliations
Background: Influenza is a pervasive respiratory infection which disproportionately burdens long-term care residents. To limit outbreaks, guidelines recommend antiviral prophylaxis, particularly oseltamivir or zanamivir, despite acknowledging the inadequate supporting evidence. Therefore, we aimed to review the literature on the efficacy of oseltamivir, zanamivir, and baloxavir prophylaxis for influenza in long-term care.
Methods: Medline, Embase, PubMed, and several other databases were searched from inception to August 16, 2023. For inclusion, observational studies or randomized controlled trials (RCTs) had to report influenza-like illness (ILI) or infection rates amongst adult long-term care populations receiving prophylaxis. Outcome values were meta-analyzed as intervention-specific pooled proportions (PPs) and risk ratios (RRs) when applicable. Risk of bias was assessed via the Cochrane risk of bias tool 2.0 and Joanna Briggs Institute checklist.
Results: In total, 14 studies were included, comprising 12,672 residents. Individuals given oseltamivir or zanamivir experienced the fewest symptomatic, test-confirmed infections (oseltamivir PP: 0.7%, 95%CI: 0.1-4.7%, zanamivir PP: 3.0%, 95%CI: 0.9-9.4%) and ILIs (oseltamivir PP: 2.8%, 95%CI: 1.8-4.3%, zanamivir PP: 3.4%, 95%CI: 1.3-7.2%). However, no significant statistical differences were detected versus most other interventions (ILI PP range: 4.5-6.4%, infection PP range: 4.6-7.9%). Similarly, in studies directly comparing either antiviral to placebo, there were no associated benefits despite every RR being below 1 (0.51-0.75) due to expansive 95%CIs.
Conclusions: Oseltamivir or zanamivir could provide some benefit but low statistical power behind most estimates precluded definitive conclusions. Therefore, additional studies (RCTs) are needed to expand the evidence base and validate whether prophylaxis is beneficial in this setting.
Keywords: influenza; long-term care; nursing home; oseltamivir; zanamivir.
. 2025 Mar 8:ciaf101.
doi: 10.1093/cid/ciaf101. Online ahead of print. Evaluation of influenza antiviral prophylaxis for long-term care residents: a systematic review and meta-analysis
Ryan Hanula[SUP] 1 2 [/SUP], Jessica Glugosh[SUP] 3 [/SUP], Elise Van Leer[SUP] 4 [/SUP], Émilie Bortolussi-Courval[SUP] 1 2 [/SUP], Connor Prosty[SUP] 5 [/SUP]
Affiliations
- PMID: 40056452
- DOI: 10.1093/cid/ciaf101
Background: Influenza is a pervasive respiratory infection which disproportionately burdens long-term care residents. To limit outbreaks, guidelines recommend antiviral prophylaxis, particularly oseltamivir or zanamivir, despite acknowledging the inadequate supporting evidence. Therefore, we aimed to review the literature on the efficacy of oseltamivir, zanamivir, and baloxavir prophylaxis for influenza in long-term care.
Methods: Medline, Embase, PubMed, and several other databases were searched from inception to August 16, 2023. For inclusion, observational studies or randomized controlled trials (RCTs) had to report influenza-like illness (ILI) or infection rates amongst adult long-term care populations receiving prophylaxis. Outcome values were meta-analyzed as intervention-specific pooled proportions (PPs) and risk ratios (RRs) when applicable. Risk of bias was assessed via the Cochrane risk of bias tool 2.0 and Joanna Briggs Institute checklist.
Results: In total, 14 studies were included, comprising 12,672 residents. Individuals given oseltamivir or zanamivir experienced the fewest symptomatic, test-confirmed infections (oseltamivir PP: 0.7%, 95%CI: 0.1-4.7%, zanamivir PP: 3.0%, 95%CI: 0.9-9.4%) and ILIs (oseltamivir PP: 2.8%, 95%CI: 1.8-4.3%, zanamivir PP: 3.4%, 95%CI: 1.3-7.2%). However, no significant statistical differences were detected versus most other interventions (ILI PP range: 4.5-6.4%, infection PP range: 4.6-7.9%). Similarly, in studies directly comparing either antiviral to placebo, there were no associated benefits despite every RR being below 1 (0.51-0.75) due to expansive 95%CIs.
Conclusions: Oseltamivir or zanamivir could provide some benefit but low statistical power behind most estimates precluded definitive conclusions. Therefore, additional studies (RCTs) are needed to expand the evidence base and validate whether prophylaxis is beneficial in this setting.
Keywords: influenza; long-term care; nursing home; oseltamivir; zanamivir.